Company Description
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer.
The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.
The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 20, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 331 |
| CEO | Philip Astley-Sparke F.S.A. |
Contact Details
Address: 500 Unicorn Park Woburn, Massachusetts 01801 United States | |
| Phone | (781) 222-9600 |
| Website | replimune.com |
Stock Details
| Ticker Symbol | REPL |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001737953 |
| CUSIP Number | 76029N106 |
| ISIN Number | US76029N1063 |
| Employer ID | 82-2082553 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sushil Patel Ph.D. | Chief Executive Officer |
| Philip Astley-Sparke F.S.A. | Executive Chairman |
| Dr. Robert Coffin Ph.D. | Founder, Chief Scientist and Director |
| Emily Luisa Hill | Chief Financial Officer |
| Andrew Schwendenman | Chief Accounting Officer and Treasurer |
| Christopher Sarchi | Chief Commercial Officer |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Paul Bullock | Chief Manufacturing Officer and Framingham Site Head |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 22, 2024 | EFFECT | Notice of Effectiveness |
| Jul 19, 2024 | ARS | Filing |
| Jul 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 19, 2024 | DEF 14A | Other definitive proxy statements |
| Jul 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 144 | Filing |
| Jun 6, 2024 | 8-K | Current Report |
| Jun 3, 2024 | 8-K | Current Report |
| May 23, 2024 | 144 | Filing |